Last reviewed · How we verify
DA-EPOCH-R for DLBCL, PTLD, AND PMBCL — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
DA-EPOCH-R for DLBCL, PTLD, AND PMBCL (DA-EPOCH-R for DLBCL, PTLD, AND PMBCL) — Baylor College of Medicine.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DA-EPOCH-R for DLBCL, PTLD, AND PMBCL TARGET | DA-EPOCH-R for DLBCL, PTLD, AND PMBCL | Baylor College of Medicine | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DA-EPOCH-R for DLBCL, PTLD, AND PMBCL CI watch — RSS
- DA-EPOCH-R for DLBCL, PTLD, AND PMBCL CI watch — Atom
- DA-EPOCH-R for DLBCL, PTLD, AND PMBCL CI watch — JSON
- DA-EPOCH-R for DLBCL, PTLD, AND PMBCL alone — RSS
Cite this brief
Drug Landscape (2026). DA-EPOCH-R for DLBCL, PTLD, AND PMBCL — Competitive Intelligence Brief. https://druglandscape.com/ci/da-epoch-r-for-dlbcl-ptld-and-pmbcl. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab